PMID- 35415025
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 14
IP  - 3
DP  - 2022 Mar
TI  - Clinical Response of Nuberol Forte(R) for Pain Management With Musculoskeletal 
      Conditions in Routine Pakistani Practice (NFORTE-EFFECT).
PG  - e23011
LID - 10.7759/cureus.23011 [doi]
LID - e23011
AB  - Background Musculoskeletal pain is the most common complaint presented to the 
      health practitioner. It is well-known that untreated or under-treated pain can 
      have a significant negative impact on an individual's quality of life (QoL). 
      Objectives The current study aimed to assess the clinical response of Nuberol 
      Forte(R) (paracetamol 650 mg + orphenadrine 50 mg) to musculoskeletal pain in 
      routine Pakistani practice and its impact on improving the patient's QoL. Methods 
      A prospective, observational multicenter study (NFORT-EFFECT: Safety & Efficacy 
      of Nuberol Forte in Pain Management). Three hundred ninety-nine patients with 
      known prescreened musculoskeletal pain were recruited from 10 major healthcare 
      facilities across six (6) major cities of Pakistan, as per the 
      inclusion/exclusion criteria. After the baseline visit (Visit 1), the patients 
      were followed up one to two weeks (Visit 2) after the treatment as per the 
      physician's discretion. Data were collected using the Case Report Form (CRF) 
      designed for the study, and adverse events (AEs) were also monitored to assess 
      drug safety. Pain intensity was assessed through a visual analog scale (VAS), and 
      QoL was assessed using the Muscle and Joint Measure (MJM) scale. Results Out of 
      399 enrolled patients, 49.4% were males and 50.6% were females with a mean age of 
      47.24 +/- 14.20 years. Most patients were presented with knee osteoarthritis (OA), 
      i.e., 148 (38%), followed by backache 70 (18.2%). A significant reduction in the 
      mean pain score was observed after treatment with the combination of paracetamol 
      and orphenadrine (p<0.05). Furthermore, an overall improvement in the patient's 
      QoL was also observed. During the study, only 10 patients reported mild adverse 
      events (AEs), namely, dryness of the mouth, dizziness, gastric irritation, 
      tachycardia, restlessness, etc. Conclusion The combination of paracetamol 
      and orphenadrine (Nuberol Forte) exhibited effective pain management among 
      patients with musculoskeletal conditions and improved their QoL.
CI  - Copyright (c) 2022, Noor et al.
FAU - Noor, Syed Shahid
AU  - Noor SS
AD  - Orthopedics and Trauma, Liaquat National Hospital and Medical College, Karachi, 
      PAK.
FAU - Najjad, Muhammad Kazim
AU  - Najjad MK
AD  - Orthopedic Surgery, Liaquat National Hospital, Karachi, PAK.
FAU - Ahmed, Nasir
AU  - Ahmed N
AD  - Orthopedics, Liaquat University of Medical and Health Sciences, Jamshoro, PAK.
FAU - Anwar, Khurram
AU  - Anwar K
AD  - Periodontology, Isra University Hospital, Hyderabad, PAK.
FAU - Memon, Abdul
AU  - Memon A
AD  - Family Medicine, Family Clinic, Mirpurkhas, PAK.
FAU - Riaz, Tehseen
AU  - Riaz T
AD  - Orthopedic Surgery, Jinnah Hospital, Lahore, PAK.
FAU - Hanif, Muhammad
AU  - Hanif M
AD  - Orthopedic Surgery, Lahore General Hospital, Lahore, PAK.
FAU - Maqbool, Nauman
AU  - Maqbool N
AD  - Orthopedic Surgery, Fauji Foundation, Rawalpindi, PAK.
FAU - Ahmed, Saeed
AU  - Ahmed S
AD  - Orthopedics, Life Care International Hospital, Islamabad, PAK.
FAU - Ahmed, Israr
AU  - Ahmed I
AD  - Orthopedics and Spinal Surgery, Hayatabad Medical Complex, Peshawar, PAK.
FAU - Khanzada, Ali Yasir
AU  - Khanzada AY
AD  - Clinical Research, The Searle Company Limited, Karachi, PAK.
LA  - eng
PT  - Journal Article
DEP - 20220309
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC8994056
OTO - NOTNLM
OT  - effectiveness
OT  - musculoskeletal pain
OT  - orphenadrine/paracetamol combination
OT  - pain management
OT  - pakistani population
OT  - quality of life
OT  - safety
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/04/14 06:00
MHDA- 2022/04/14 06:01
PMCR- 2022/03/09
CRDT- 2022/04/13 05:35
PHST- 2022/03/07 00:00 [accepted]
PHST- 2022/04/13 05:35 [entrez]
PHST- 2022/04/14 06:00 [pubmed]
PHST- 2022/04/14 06:01 [medline]
PHST- 2022/03/09 00:00 [pmc-release]
AID - 10.7759/cureus.23011 [doi]
PST - epublish
SO  - Cureus. 2022 Mar 9;14(3):e23011. doi: 10.7759/cureus.23011. eCollection 2022 Mar.